Peritoneal papillary serous carcinoma: response to Taxol in platinum resistant disease.
A case of peritoneal papillary serous carcinoma which developed after total abdominal hysterectomy and bilateral salpingo-oophorectomy for a benign condition is presented. The patient was treated with platinum-based chemotherapy to which she initially responded, but then the tumor progressed. High dose paclitaxel (250 mg/m2) was given. The patient tolerated this treatment well, achieving a rapid partial response with good palliation of symptoms. Paclitaxel should be considered for patients with a platinum resistant peritoneal papillary serous carcinoma.
Wilailak
S
S
Ramathibodi Hospital, Bangkok, Thailand.
Kudelka
A P
AP
Donner
L R
LR
Silva
E
E
Mante
R
R
Kavanagh
J J
JJ
D016190:Carboplatin / Q000627:therapeutic use; D018283:Cystadenocarcinoma, Papillary / Q000188:drug therapy*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D010534:Peritoneal Neoplasms / Q000188:drug therapy*
D016190:Carboplatin; D017239:Paclitaxel